NCT00291668 - Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2006

Primary Completion Date

November 8, 2007

Study Completion Date

November 8, 2007

Conditions

Crohn's Disease

Interventions

BIOLOGICAL

Certolizumab Pegol

"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"

OTHER

Placebo

"* Active Substance: isotonic sodium chloride solution~* Pharmaceutical Form: Solution for injection~* Concentration: 1 mL~* Route of Administration: Subcutaneous use"

Trial Locations (22)

Unknown

Aichi-Gun

Nagoya

Toyoake

Toyohashi

Kashiwa

Sakura

Chikusino

Asahikawa

Sapporo

Nishinomiya

Yokohama

Miyazaki-gun

Kurashiki

Tyuto-gun

Suita

Ōtsu

Shinjyuku

Fukuoka

Kagoshima

Nagasaki

Niigata

Osaka